Mirum Pharmaceuticals Eyes $650M Sales as Pipeline Catalysts Loom
Event summary
- Mirum Pharmaceuticals reported $521.3M in 2025 net product sales, up 55% YoY.
- 2026 guidance set at $630M–$650M in global net product sales.
- Four potential registrational readouts expected in next 18 months.
- Completed acquisition of Bluejay Therapeutics for brelovitug rights in HDV.
- LIVMARLI sales grew 69% YoY to $360M, Bile Acid Medicines up 31% to $161.3M.
The big picture
Mirum's strategic focus on rare disease therapies positions it in a high-growth niche, but success hinges on delivering on four near-term pipeline catalysts. The Bluejay acquisition expands its HDV footprint, while LIVMARLI's commercial momentum underscores the potential of its cholestatic pruritus franchise. The company's ability to execute across regulatory milestones and commercial expansion will determine its trajectory in a competitive biopharma landscape.
What we're watching
- Pipeline Momentum
- Whether topline data from VISTAS (PSC) and AZURE-1 (HDV) studies meet expectations in 2026.
- Commercial Execution
- The pace at which Mirum can sustain LIVMARLI's 69% YoY growth amid expanding global reach.
- Financial Discipline
- How Mirum balances rising operating expenses ($543.4M in 2025) with pipeline investments.
Related topics